Jiang X, Xu W, Sun J, Lin J, Lin Z, Lian X
Cell Biol Toxicol. 2025; 41(1):48.
PMID: 39979480
PMC: 11842480.
DOI: 10.1007/s10565-025-09999-1.
Sebastian-Perez R, Nakagawa S, Tu X, Aranda S, Pesaresi M, Gomez-Garcia P
Elife. 2025; 12.
PMID: 39969508
PMC: 11839162.
DOI: 10.7554/eLife.87742.
Li J, Lin X, Xie L, Zhao J, Han C, Deng H
Life Med. 2025; 2(4):lnad037.
PMID: 39872545
PMC: 11749542.
DOI: 10.1093/lifemedi/lnad037.
Neugebauer E, Walter S, Tan J, Drayman N, Franke V, van Gent M
Nat Commun. 2025; 16(1):710.
PMID: 39814710
PMC: 11735616.
DOI: 10.1038/s41467-025-55928-5.
Diaz-Ubilla M, Retamal M
Int J Mol Sci. 2025; 26(1.
PMID: 39796228
PMC: 11719937.
DOI: 10.3390/ijms26010373.
MARTRE family proteins negatively regulate CCR4-NOT activity to protect poly(A) tail length and promote translation of maternal mRNA.
Yang J, Bu J, Liu B, Liu Y, Zhang Z, Li Z
Nat Commun. 2025; 16(1):248.
PMID: 39747175
PMC: 11696134.
DOI: 10.1038/s41467-024-55610-2.
Zscan4 mediates ubiquitination and degradation of the corepressor complex to promote chromatin accessibility in 2C-like cells.
Yang J, Dan J, Zhao N, Liu L, Wang H, Liu Q
Proc Natl Acad Sci U S A. 2024; 121(52):e2407490121.
PMID: 39705314
PMC: 11670194.
DOI: 10.1073/pnas.2407490121.
Transposable element activity captures human pluripotent cell states.
Levin-Ferreyra F, Kodali S, Cui Y, Pashos A, Pessina P, Brumbaugh J
EMBO Rep. 2024; 26(2):329-352.
PMID: 39668246
PMC: 11772670.
DOI: 10.1038/s44319-024-00343-y.
Capture of Totipotency in Mouse Embryonic Stem Cells in the Absence of Pdzk1.
Zhang W, Zhao Y, Yang Z, Yan J, Wang H, Nie S
Adv Sci (Weinh). 2024; 12(6):e2408852.
PMID: 39630006
PMC: 11809344.
DOI: 10.1002/advs.202408852.
SIX transcription factors are necessary for the activation of DUX4 expression in facioscapulohumeral muscular dystrophy.
Fox A, Oliva J, Vangipurapu R, Sverdrup F
Skelet Muscle. 2024; 14(1):30.
PMID: 39627769
PMC: 11613756.
DOI: 10.1186/s13395-024-00361-3.
The maternal-to-zygotic transition: reprogramming of the cytoplasm and nucleus.
Kojima M, Hoppe C, Giraldez A
Nat Rev Genet. 2024; .
PMID: 39587307
DOI: 10.1038/s41576-024-00792-0.
The impact of retrotransposons on zygotic genome activation and the chromatin landscape of early embryos.
Solberg T, Kobayashi-Ishihara M, Siomi H
Ann N Y Acad Sci. 2024; 1542(1):11-24.
PMID: 39576233
PMC: 11668504.
DOI: 10.1111/nyas.15260.
From the genome's perspective: Bearing somatic retrotransposition to leverage the regulatory potential of L1 RNAs.
Mangoni D, Mazzetti A, Ansaloni F, Simi A, Tartaglia G, Pandolfini L
Bioessays. 2024; 47(2):e2400125.
PMID: 39520370
PMC: 11755705.
DOI: 10.1002/bies.202400125.
In vitro gametogenesis: Towards competent oocytes: Limitations and future improvements for generating oocytes from pluripotent stem cells in culture.
Aizawa E, Peters A, Wutz A
Bioessays. 2024; 47(1):e2400106.
PMID: 39498732
PMC: 11662156.
DOI: 10.1002/bies.202400106.
Advances in understanding the regulation of pluripotency fate transition in embryonic stem cells.
Jia Y, Yu Y, Guan L
Front Cell Dev Biol. 2024; 12:1494398.
PMID: 39479513
PMC: 11521825.
DOI: 10.3389/fcell.2024.1494398.
The pluripotent-to-totipotent state transition in mESCs activates the intrinsic apoptotic pathway through DUX-induced DNA replication stress.
Jia S, Wen X, Zhu M, Fu X
Cell Mol Life Sci. 2024; 81(1):440.
PMID: 39460804
PMC: 11512989.
DOI: 10.1007/s00018-024-05465-z.
Rise and SINE: roles of transcription factors and retrotransposons in zygotic genome activation.
Kravchenko P, Tachibana K
Nat Rev Mol Cell Biol. 2024; 26(1):68-79.
PMID: 39358607
DOI: 10.1038/s41580-024-00772-6.
Manipulating cell fate through reprogramming: approaches and applications.
Yagi M, Horng J, Hochedlinger K
Development. 2024; 151(19).
PMID: 39348466
PMC: 11463964.
DOI: 10.1242/dev.203090.
A molecular switch from tumor suppressor to oncogene in ER+ve breast cancer: Role of androgen receptor, JAK-STAT, and lineage plasticity.
Asemota S, Effah W, Holt J, Johnson D, Cripe L, Ponnusamy S
Proc Natl Acad Sci U S A. 2024; 121(40):e2406837121.
PMID: 39312663
PMC: 11459127.
DOI: 10.1073/pnas.2406837121.
Oligonucleotide Therapies for Facioscapulohumeral Muscular Dystrophy: Current Preclinical Landscape.
Beck S, Yokota T
Int J Mol Sci. 2024; 25(16).
PMID: 39201751
PMC: 11354670.
DOI: 10.3390/ijms25169065.